Immedica Pharma

Immedica is a pan-European pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care. Founded in 2018, Immedica serves patients across more than 50 countries, with commercial field presence throughout Europe, an office in Dubai covering the Middle East and North Africa, and an office in Chicago covering North America. The company therapeutic areas span rare metabolic diseases, rare hematology and oncology, rare neurology, rare endocrinology, and specialty care. Immedica is backed by investment firms Impilo and KKR and has grown from 7 employees at founding to over 140 employees and a turnover exceeding SEK 1 billion.